Sun Pharma, SPARC get nod from USFDA for SEZABY

18 Nov 2022 Evaluate

Sun Pharmaceutical Industries and Sun Pharma Advanced Research Company (SPARC) have received approval from U.S. Food and Drug Administration (USFDA) for SEZABY (phenobarbital sodium powder for injection) for the treatment of neonatal seizures. With this approval, SEZABY becomes the first and only product specifically indicated in the U.S. for the treatment of neonatal seizures in term and preterm infants. SEZABY is expected to be available in the U.S. in Q4FY23.

SEZABY is a benzyl alcohol-free and propylene glycol-free formulation of phenobarbital sodium powder for injection. It was granted orphan drug designation by the US FDA for the treatment of neonatal seizures. SEZABY was recently licensed by SPARC to Sun Pharma. Under the terms of the license agreement, SPARC is eligible to receive a milestone payment on approval of SEZABY by the US FDA.

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Sun Pharma Inds. Share Price

1631.15 -0.50 (-0.03%)
27-Jan-2026 11:14 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.15
Dr. Reddys Lab 1239.05
Cipla 1304.00
Zydus Lifesciences 889.90
Lupin 2136.10
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×